Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
201-220 of 936 trials

B-cell Non-Hodgkin Lymphoma: JNJ-90014496

We are testing a new treatment called JNJ-90014496 for adults with B-cell Non-Hodgkin Lymphoma. The goal is to see how well it works and its safety compared to existing options.

Non-Hodgkin Lymphoma>2 yearsSafety phase (I)Oncology

MK-5684 Therapies for Advanced Prostate Cancer

We are studying the safety and effectiveness of MK-5684-based treatments for men with metastatic castration-resistant prostate cancer. This research aims to find better options for managing this advanced stage of cancer.

Metastatic Castration-Resistant Prostate Cancer>2 yearsSafety phase (I)Efficacy phase (II)Standard MedicinesCost ReimbursementOncologyUrology

Radiprodil for Seizures in Tuberous Sclerosis and Focal Cortical Dysplasia

We are studying the safety and effects of radiprodil on seizures and behavior in patients with Tuberous Sclerosis Complex or Focal Cortical Dysplasia Type II. This research may help improve treatment options for these conditions.

Focal Cortical Dysplasia (FCD)Tuberous Sclerosis Complex (TSC)3-6 monthsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteNeurology

AUTO1 Treatment for Pediatric Blood Cancers

We are studying the safety and early effectiveness of AUTO1 in children with relapsed or refractory B cell acute lymphoblastic leukemia and aggressive mature B cell non-Hodgkin lymphoma. This trial aims to see how well the treatment works and how it can be safely administered.

B-cell Acute Lymphoblastic LeukemiaAggressive Mature B-cell Non-Hodgkin Lymphoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesHematologyOncology

Advanced Melanoma: RO7276389 and Cobimetinib Study

We are evaluating a new treatment for patients with advanced solid tumors or melanoma that have a specific genetic mutation. This study looks at the safety and early effects of the treatment alone and in combination with another drug.

Metastatic Melanoma>2 yearsSafety phase (I)Oncology

Melanoma Treatment: Pembrolizumab with New Agents

We are studying the safety and effectiveness of pembrolizumab alone or with new investigational treatments for people with melanoma. This research aims to find better options for managing this type of skin cancer.

Melanoma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Bladder Cancer: Pembrolizumab and Enfortumab Combination

We are studying a combination of two medications for patients with first-line metastatic urothelial carcinoma. The aim is to evaluate their safety and effectiveness in treating this advanced cancer.

Bladder CancerSafety phase (I)Efficacy phase (II)Oncology

Advanced Urothelial Carcinoma: MK-2870 with Enfortumab Vedotin

We are studying a new treatment combining MK-2870 with Enfortumab Vedotin and Pembrolizumab for patients with advanced bladder cancer. The goal is to assess safety and how well it works compared to existing options.

Bladder Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Advanced Non-Small Cell Lung Cancer: JNJ-86974680 Study

We are exploring a new treatment for advanced non-small cell lung cancer using JNJ-86974680 alone and with other therapies. The goal is to see how well it works in combination with cetrelimab and radiotherapy.

Advanced Non-Small Cell Lung Cancer>2 yearsSafety phase (I)OncologyPulmonology

Immuno-OCT Imaging: Safety and Feasibility Study

We are exploring a new imaging technique using a tracer for patients undergoing endoscopy. The goal is to determine if this method is safe and effective for better visualization during procedures.

Barrett's EsophagusColon CarcinomaGastrointestinal DysplasiaSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology

IDOR-1134-2831 Vaccine: Healthy Participants Study

We are evaluating a new vaccine in healthy individuals to see how it is administered and its effects. This study aims to understand its safety and how the body responds to it.

Clostridium Difficile Infection>2 yearsSafety phase (I)Infectious Diseases

Repotrectinib for Advanced Cancers in Kids and Young Adults

We are studying a new treatment for children and young adults with advanced cancers that have specific genetic changes. The trial aims to evaluate how well it works and its safety.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPediatrics

Advanced Cancer: JNJ-87704916 Tumor-Targeting Virus

We are testing a new virus that targets tumors in patients with advanced cancer. The goal is to see if it can effectively attack cancer cells when injected directly into the tumor.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Colorectal Cancer: Amivantamab Treatment Study

We are studying the effects of amivantamab alone and with standard chemotherapy for patients with advanced colorectal cancer. The goal is to see how well it works and to ensure it is safe.

Advanced or Metastatic Colorectal CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Healthy Men: Study of Inno8 Dosing

We are researching how different doses of the medicine Inno8 work in the bodies of healthy men. This study may help us understand the best dosing for future treatments.

Haemophilia A1-2 yearsSafety phase (I)AllergologyDermatologyDiabetologyEndocrinologyGynecology and ObstetricsHematologyInfectious DiseasesInternal MedicineNephrologyNeurologyOncologyOphthalmologyOrthopedics and TraumatologyOtolaryngologyPediatricsPsychiatryRheumatologyUrology

Metastatic Lung Cancer: BL-B01D1 Treatment

We are evaluating a new treatment for patients with metastatic or unresectable non-small cell lung cancer and other solid tumors. The study aims to assess its safety and how well it is tolerated.

Non-small Cell Lung Cancer1-2 yearsSafety phase (I)OncologyPulmonology

New Imaging Tracer for Liver and GI Diseases

We are investigating a special imaging agent in healthy people and patients with liver and gastrointestinal conditions. This study aims to see how effectively it binds to specific receptors related to these diseases.

Crohn’s DiseasePrimary Sclerosing CholangitisMetabolic Dysfunction-Associated Steatotic Liver DiseaseSafety phase (I)GastroenterologyHepatologyInternal Medicine

Acute Myeloid Leukemia: CLN-049 Treatment Study

We are testing a new treatment called CLN-049 for patients with acute myeloid leukemia who have measurable residual disease. This study aims to find the right dose and assess its safety.

Acute Myeloid Leukemia>2 yearsSafety phase (I)HematologyOncology

Acute Leukemia: Bleximenib Study

We are testing a new drug called Bleximenib for people with acute leukemia to find the best dose and check its safety. We also want to see if it helps improve treatment outcomes.

Acute Leukemia>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesHematology

Acute Myeloid Leukemia: Bleximenib Treatment Study

We are testing a new drug, bleximenib, combined with current therapies for patients with acute myeloid leukemia who have certain genetic changes. The goal is to find the best dose and ensure it is safe for use.

Acute Myeloid Leukemia>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncology